PODCAST · health
Oncology podcast on PDT (Dr Nazar Vasyliv)
by Andrew Campbell
His study significantly shapes our understanding of glioblastoma treatment by introducing an innovative approach that combines photodynamic therapy (PDT) with necroptosis induction. By targeting glioblastoma stem cells—those most resistant to conventional therapies—this method offers new possibilities for more precise surgical outcomes, reduced recurrence, and the development of personalised treatment strategies. Findings demonstrate that inducing necroptosis, a regulated form of cell death, following PDT could bring about notable clinical benefits, particularly by addressing glioblastoma’s well-known resistance to apoptosis. This marks an important advancement in tackling the complexities of glioblastoma treatment, with the potential to improve therapeutic outcomes and extend survival rates for patients facing this aggressive brain tumour.dx.doi.org/10.13140/RG.2.2.2860
No episodes available yet.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
His study significantly shapes our understanding of glioblastoma treatment by introducing an innovative approach that combines photodynamic therapy (PDT) with necroptosis induction. By targeting glioblastoma stem cells—those most resistant to conventional therapies—this method offers new possibilities for more precise surgical outcomes, reduced recurrence, and the development of personalised treatment strategies. Findings demonstrate that inducing necroptosis, a regulated form of cell death, following PDT could bring about notable clinical benefits, particularly by addressing glioblastoma’s well-known resistance to apoptosis. This marks an important advancement in tackling the complexities of glioblastoma treatment, with the potential to improve therapeutic outcomes and extend survival rates for patients facing this aggressive brain tumour.dx.doi.org/10.13140/RG.2.2.2860
HOSTED BY
Andrew Campbell
Loading similar podcasts...